GlassScriptPhysician profile
Nicholas Biasotto
NPI 1164458485
$3,801.16
in general payments reported to CMS, 2019-2025
42 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $574 · 2021: $718 · 2022: $432 · 2023: $634 · 2024: $446 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.80 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $520.42 | 2021-2023 | Qulipta, Vraylar, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $425.80 | 2019-2025 | Relistor, Xifaxan |
| Lilly USA, LLC | $306.95 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $296.70 | 2020-2025 | |
| Amgen INC. | $245.78 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $194.21 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $171.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $148.64 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $135.05 | 2023 | Veozah, Myrbetriq |
| Paratek Pharmaceuticals, INC. | $113.35 | 2024-2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $110.44 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $95.59 | 2021-2025 | Breztri |
| Alkermes, INC. | $88.41 | 2024-2025 | Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $75.26 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.82 | 2020-2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $60.42 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $58.97 | 2025 | Rexulti |
| Eisai INC. | $57.83 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $46.33 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $44.33 | 2025 | |
| Allergan, INC. | $41.75 | 2019-2020 | |
| Kvk-Tech, INC. | $38.47 | 2025 | |
| Boston Scientific Corporation | $37.55 | 2025 | Bodyguardian, Wavewriter Alpha Prime 16 |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $37.47 | 2024-2025 | Rexulti |
| Tactile Systems Technology INC | $33.14 | 2025 | Nimbl, Flexitouch Plus |
| Lundbeck LLC | $31.20 | 2025 | Rexulti |
| Abbott Laboratories | $29.61 | 2022-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $29.43 | 2024-2025 | Keveyis, Gvoke Hypopen |
| G Medical Diagnostic Services, INC. | $29.42 | 2022-2023 | Cardiac Monitoring Suite |
| Kowa Pharmaceuticals America, INC. | $26.66 | 2019-2022 | |
| Insulet Corporation | $26.10 | 2025 | Omnipod |
| Smith+Nephew, INC. | $24.87 | 2019 | |
| Exact Sciences Corporation | $20.62 | 2025 | The Cologuard Plus Collection Kit |
| Indivior INC. | $17.29 | 2024 | Sublocade |
| Novartis Pharmaceuticals Corporation | $17.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.86 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $15.70 | 2021 | |
| Evoke Pharma, INC. | $15.32 | 2025 | |
| Tonix Medicines, INC. | $14.87 | 2025 | Tonmya |
| Almatica Pharma LLC | $14.24 | 2023 | Gralise |
| Cashflow Solutions, LLC | $14.16 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Melinta Therapeutics, LLC | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Biasotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.